EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood

Lucía Bailón, Maria C Puertas, Maria C García-Guerrero, Igor Moraes-Cardoso iD, Ester Aparicio, Yovaninna Alarcón-Soto iD, Angel Rivero, Elias P Rosen iD, Jacob D Estes iD, Julià Blanco, Alex Olvera iD, Beatriz Mothe iD und 3 weitere

The Journal of Infectious Diseases · 17.03.2025 · 231 (3) · 600-610

DOI: 10.1093/infdis/jiae530 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.10.2024. Verfasst von Lucía Bailón und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Lamivudine, HIV Infections, HIV-1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fundació Lluita Contra les Infeccions, NIAID NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare the effects of first-line antiretroviral therapy (ART) with dolutegravir plus lamivudine (DTG + 3TC) versus dolutegravir plus emtricitabine/tenofovir alafenamide (DTG + FTC/TAF) on the human immunodeficiency virus type 1 (HIV-1) reservoir and immune activation biomarkers in people with HIV (PWH).

Methods

DUALITY was a 48-week, single-center, randomized, open-label clinical trial in ART-naive PWH, randomized (1:1) to receive ART with DTG + 3TC (2DR group) or DTG + FTC/TAF (3DR group). We measured total and intact proviral HIV-1 DNA, cell-associated RNA in CD4+ T cells, frequency of HIV-infected CD4+ T cells able to produce p24, plasma soluble inflammatory markers, and activation and exhaustion markers in CD4+ and CD8+ T cells.

Results

Forty-four participants (22 per study arm) were enrolled, with baseline mean (standard deviation) log10 plasma viral load (pVL) 4.4 (0.7) copies/mL and CD4+ T-cell counts of 493 (221) cells/μL. At week 48, all participants had pVL <50 copies/mL at week 48, except for 1 participant in the 2DR group who was resuppressed after treating syphilis. Changes from baseline in reservoir parameters and immune biomarkers were comparable between groups.

Conclusions

First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC/TAF, supporting DTG/3TC among preferred first-line ART options for PWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingLamivudineHIV InfectionsHIV-1Anti-HIV AgentsHumansPyridonesOxazinesPiperazinesMaleFemaleAdultMiddle AgedBiomarkersViral LoadCD4-Positive T-LymphocytesDrug Therapy, CombinationRNA, ViralEmtricitabineCD8-Positive T-LymphocytesDolutegravir

Stichwörter der Autor:innen

HIV infectionHIV reservoirdolutegravir/lamivudinedual antiretroviral therapyimmune activation

Substanzen

PyridonesOxazinesHeterocyclic Compounds, 3-RingPiperazinesLamivudineBiomarkersAnti-HIV AgentsRNA, ViralEmtricitabineDolutegravir

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol.
  • Fundació Lluita contra les Infeccions.
  • Institute for Health Science Research Germans Trias i Pujol, Badalona.
  • Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid.
  • IrsiCaixa, Badalona.
  • Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Cerdanyola del Vallés.

ORCID-Profile: Igor Moraes-Cardoso, Yovaninna Alarcón-Soto, Elias P Rosen, Jacob D Estes, Alex Olvera, Beatriz Mothe, José Moltó

Förderung

  • Fundació Lluita Contra les Infeccions
  • NIAID NIH HHS
  • Wellcome Trust
  • National Institute for Allergy and Infectious Diseases
  • ViiV Healthcare

Zitieren

APA

Bailón, L., Puertas, M. C., García-Guerrero, M. C., Moraes-Cardoso, I., Aparicio, E., Alarcón-Soto, Y., Rivero, A., Rosen, E. P., Estes, J. D., Blanco, J., Olvera, A., Mothe, B., Martinez-Picado, J., Moltó, J., & DUALITY Study Group (2025). Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. The Journal of Infectious Diseases, 231(3), 600-610. https://doi.org/10.1093/infdis/jiae530

Vancouver

Bailón L, Puertas MC, García-Guerrero MC, Moraes-Cardoso I, Aparicio E, Alarcón-Soto Y, et al. Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. The Journal of Infectious Diseases. 2025;231(3):600-610. doi:10.1093/infdis/jiae530

BibTeX
@article{Bailn2025,
  author = {Bailón, Lucía and Puertas, Maria C and García-Guerrero, Maria C and Moraes-Cardoso, Igor and Aparicio, Ester and Alarcón-Soto, Yovaninna and Rivero, Angel and Rosen, Elias P and Estes, Jacob D and Blanco, Julià and Olvera, Alex and Mothe, Beatriz and Martinez-Picado, Javier and Moltó, José and DUALITY Study Group, DUALITY Study Group},
  title = {Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {231},
  number = {3},
  pages = {600--610},
  doi = {10.1093/infdis/jiae530}
}
Kostenlos starten →